The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Real-world first-line chemo-immunotherapy use in US and Korean BTC cases
Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, South Korea, provides an overview of a retrospective cohort study comparing real-world outcomes and post-progression treatment patterns in patients with advanced biliary tract cancer (aBTC) receiving first-line gemcitabine-platinum plus immune checkpoint inhibitors at US and Korean centers. Outcomes were broadly comparable, with differences in post-progression survival that may reflect variation in tumor subtype distribution and greater use of molecularly matched therapies after progression. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
